Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.

The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.

Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

bDepartments of Epidemiology and Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA cClinical and Translational Epidemiology Unit and Division of Gastroenterology, ...

bDepartments of Epidemiology and Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA cClinical and Translational Epidemiology Unit and Division of Gastroenterology, ...

Send your kids to these sites to help them learn, study, indulge their curiosity, and get a fresh perspective on academic subjects. I've been contributing to PCMag since 2011 in a variety of ways ...

Shop online from these top options we’ve tested. Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links ...

The European MINDACT (Microarray In Node negative Disease may Avoid ChemoTherapy) trial will directly compare a gene-signature-based decision with an Adjuvant!-Online-based decision for cases in ...